Evidence map›Paper›PMID 42835771›Full record

ArticleClinical, cosmetic and investigational dermatology2026

Insulin Resistance as a Potential Predictor of Post-Inflammatory Hyperpigmentation After CO

Sihem Benosman, Qiaofeng Zhao, Yuping Ran, Xueqin Huang, Alberto Leguina-Ruzzi

Abstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sihem BenosmanStetika Medical Center, Oran, Algeria.
Qiaofeng ZhaoJuntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan.ORCID 0000-0001-7407-4043
Yuping RanDepartment of Dermatology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.ORCID 0000-0002-9382-0571
Xueqin HuangThe First Dongguan Affiliated Hospital, Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, School of Medical Technology, Guangdong Medical University, Dongguan, People's Republic of China.
Alberto Leguina-RuzziFaculty of Medicine, Universidad Andrés Bello, Santiago, Chile.ORCID 0000-0002-4761-3491

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Laser-assisted skin regeneration is a cornerstone of modern dermatologic practice; however, post-inflammatory hyperpigmentation (PIH) remains a major limiting complication of CO Patients and Methods: A prospective, non-randomized, real-world study included 45 patients treated in a private practice in the Maghreb region, characterized by high UV exposure and predominantly medium-to-high phototypes. The Dual Technique combined ablative fractional vaporization with subablative thermal stimulation. Skin quality was assessed using the Vancouver Scar Scale (VSS), and PIH severity using the Dermal Pigmentation Area and Severity Index (DPASI). Outcomes were analyzed in relation to phototype, HOMA-IR, and polycystic ovary syndrome (PCOS). Results: Significant clinical improvement was observed across indications following treatment, typically within two sessions. PIH occurred in 15/20 (75%) patients with Fitzpatrick phototypes I-III compared with 9/25 (36%) patients with phototypes IV-VI (p = 0.0092). PIH severity showed a strong positive correlation with HOMA-IR (Spearman Conclusion: The Dual Technique CO

Indexed as

CO2 laserfractional laser resurfacinginsulin resistancepolycystic ovary syndromepost-inflammatory hyperpigmentationskin phototypeultraviolet radiation

Identifiers

PMID42835771
PMCPMC13637656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.